Metabolomic analysis of plasma biomarkers in children with autism spectrum disorders

Abstract

Autism spectrum disorder (ASD) presents a significant risk to human well-being and has emerged as a worldwide public health concern. Twenty-eight children with ASD and 33 healthy children (HC) were selected for the quantitative determination of their plasma metabolites using an ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) platform. A total of 1997 metabolites were detected in the study cohort, from which 116 metabolites were found to be differentially expressed between the ASD and HC groups. Through analytical algorithms such as least absolute shrinkage selection operator (LASSO), support vector machine (SVM), and random forest (RF), three potential metabolic markers were identified as FAHFA (18:1(9Z)/9-O-18:0), DL-2-hydroxystearic acid, and 7(S),17(S)-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid. These metabolites demonstrated superior performance in distinguishing the ASD group from the HC group, as indicated by the area under curves (AUCs) of 0.935, 0.897, and 0.963 for the three candidate biomarkers, respectively. The samples were divided into training and validation sets according to 7:3. Diagnostic models were constructed using logistic regression (LR), SVM, and RF. The constructed three-biomarker diagnostic model also exhibited strong discriminatory efficacy. These findings contribute to advancing our understanding of the underlying mechanisms involved in the occurrence of ASD and provide a valuable reference for clinical diagnosis.

Keywords

autism spectrum disorder / biomarkers / machine learning / metabolomic / UPLC-MS/MS

References

1	A Iles. Autism spectrum disorders. Prim Care. 2021;48(3):461-473.
2	J Zeidan, E Fombonne, J Scorah, et al. Global prevalence of autism: a systematic review update. Autism Res. 2022;15(5):778-790.
3	SL Hyman, SE Levy, SM Myers, Council on Children With Disabilities SOD, Behavioral P. Identification, evaluation, and management of children with autism spectrum disorder. Pediatrics. 2020;145(1):e20193447.
4	H Zhou, X Xu, W Yan, et al. Prevalence of autism spectrum disorder in China: a nationwide multi-center population-based study among children aged 6 to 12 years. Neurosci Bull. 2020;36(9):961-971. doi:
5	KM Antshel, N Russo. Autism spectrum disorders and ADHD: overlapping phenomenology, diagnostic issues, and treatment considerations. Curr Psychiatry Rep. 2019;21(5):34.
6	L Shen, X Liu, H Zhang, J Lin, C Feng, J Iqbal. Biomarkers in autism spectrum disorders: current progress. Clin Chim Acta. 2020;502:41-54.
7	P Nt, M Ds, N Mm, M In, V Ti. Investigation of circulating serum microRNA-328-3p and microRNA-3135a expression as promising novel biomarkers for autism spectrum disorder. Balkan J Med Genet. 2018;21(2):5-12.
8	AR Bailey, H Hou, DF Obregon, et al. Aberrant T-lymphocyte development and function in mice overexpressing human soluble amyloid precursor protein-alpha: implications for autism. FASEB J. 2012;26(3):1040-1051.
9	A Cortelazzo, C De Felice, R Guerranti, et al. Expression and oxidative modifications of plasma proteins in autism spectrum disorders: interplay between inflammatory response and lipid peroxidation. Proteomics Clin Appl. 2016;10(11):1103-1112.
10	L Shen, K Zhang, C Feng, et al. iTRAQ-based proteomic analysis reveals protein profile in plasma from children with autism. Proteomics Clin Appl. 2018;12(3):e1700085.
11	M Parellada, A Andreu-Bernabeu, M Burdeus, et al. In search of biomarkers to guide interventions in autism spectrum disorder: a systematic review. Am J Psychiatry. 2023;180(1):23-40.
12	CH Johnson, J Ivanisevic, G Siuzdak. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016;17(7):451-459.
13	SJ Kim, HE Song, HY Lee, HJ Yoo. Mass spectrometry-based metabolomics in translational research. Adv Exp Med Biol. 2021;1310:509-531.
14	Z Huo, L Yu, J Yang, Y Zhu, DA Bennett, J Zhao. Corrigendum to brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis. Neurobiol Aging. 2020;91:169.
15	GJ Peng, JS Tian, XX Gao, YZ Zhou, XM Qin. Research on the pathological mechanism and drug treatment mechanism of depression. Curr Neuropharmacol. 2015;13(4):514-523.
16	N Likhitweerawong, C Thonusin, N Boonchooduang, et al. Profiles of urine and blood metabolomics in autism spectrum disorders. Metab Brain Dis. 2021;36(7):1641-1671.
17	AM Timperio, F Gevi, F Cucinotta, et al. Urinary untargeted metabolic profile differentiates children with autism from their unaffected siblings. Metabolites. 2022;12(9):797.
18	A Liu, W Zhou, L Qu, et al. Altered urinary amino acids in children with autism spectrum disorders. Front Cell Neurosci. 2019;13:7.
19	BD Needham, MD Adame, G Serena, et al. Plasma and fecal metabolite profiles in autism spectrum disorder. Biol Psychiatry. 2021;89(5):451-462.
20	X Tang, C Feng, Y Zhao, et al. A study of genetic heterogeneity in autism spectrum disorders based on plasma proteomic and metabolomic analysis: multiomics study of autism heterogeneity. MedComm. 2023;4(5):e380.
21	S Bhat, UR Acharya, H Adeli, et al. Autism: cause factors, early diagnosis and therapies. Rev Neurosci. 2014;25(6):841-850.
22	MV Ristori, SL Mortera, V Marzano, et al. Proteomics and metabolomics approaches towards a functional insight onto autism spectrum disorders: phenotype stratification and biomarker discovery. Int J Mol Sci. 2020;21(17):6274.
23	A Genovese, MG Butler. Clinical assessment, genetics, and treatment approaches in autism spectrum disorder (ASD). Int J Mol Sci. 2020;21(13):4726.
24	Z Dan, X Mao, Q Liu, et al. Altered gut microbial profile is associated with abnormal metabolism activity of autism spectrum disorder. Gut Microbes. 2020;11(5):1246-1267.
25	RS Kelly, A Boulin, N Laranjo, et al. Metabolomics and communication skills development in children; evidence from the ages and stages questionnaire. Metabolites. 2019;9(3):42.
26	T Hu, Y Dong, C He, M Zhao, Q He. The gut microbiota and oxidative stress in autism spectrum disorders (ASD). Oxid Med Cell Longev. 2020;2020:8396708.
27	S Liu, E Li, Z Sun, et al. Altered gut microbiota and short chain fatty acids in Chinese children with autism spectrum disorder. Sci Rep. 2019;9(1):287.
28	H Mazahery, CA Conlon, KL Beck, et al. A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder. J Steroid Biochem Mol Biol. 2019;187:9-16.
29	JP Schuchardt, M Huss, M Stauss-Grabo, A Hahn. Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children. Eur J Pediatr. 2010;169(2):149-164.
30	H Mazahery, W Stonehouse, M Delshad, et al. Relationship between long chain n-3 polyunsaturated fatty acids and autism spectrum disorder: systematic review and meta-analysis of case-control and randomised controlled trials. Nutrients. 2017;9(2):155.
31	H Mazahery, CA Conlon, KL Beck, et al. Inflammation (IL-1beta) modifies the effect of vitamin D and omega-3 long chain polyunsaturated fatty acids on core symptoms of autism spectrum disorder-an exploratory pilot study. Nutrients. 2020;12(3):661.
32	M Segatto, C Tonini, FW Pfrieger, V Trezza, V Pallottini. Loss of mevalonate/cholesterol homeostasis in the brain: a focus on autism spectrum disorder and Rett syndrome. Int J Mol Sci. 2019;20(13):3317.
33	CM Esposito, M Buoli, V Ciappolino, C Agostoni, P Brambilla. The role of cholesterol and fatty acids in the etiology and diagnosis of autism spectrum disorders. Int J Mol Sci. 2021;22(7):3550.
34	C Gillberg, E Fernell, E Kocovska, et al. The role of cholesterol metabolism and various steroid abnormalities in autism spectrum disorders: a hypothesis paper. Autism Res. 2017;10(6):1022-1044.
35	SA Keim, A Jude, K Smith, et al. Randomized Controlled trial of omega-3 and -6 fatty acid supplementation to reduce inflammatory markers in children with autism spectrum disorder. J Autism Dev Disord. 2022;52(12):5342-5355.